Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 13/20 | 0.49 |
| ▸ | RXRG | P48443 | 13/20 | 0.49 |
| ▸ | RXRB | P28702 | 12/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629126 | 0.92 | RXRA (0.53) | RXRARXRGRXRBAKR1B1AGBL2 | |
| SCHEMBL630423 | 0.86 | RXRA (0.58) | RXRARXRGRXRBS1PR1 | |
| Propionic Acid SCHEMBL10435305 | 0.85 | RXRA (0.43) | RXRARXRGRXRBS1PR1MRGPRX4 | |
| SCHEMBL628828 | 0.84 | F2RL3 (0.38) | RXRARXRGRXRBS1PR1MRGPRX4 | |
| SCHEMBL630830 | 0.79 | RXRA (0.43) | RXRARXRGRXRBS1PR1MRGPRX4 | |
| SCHEMBL630413 | 0.78 | RXRA (0.50) | RXRARXRGRXRBS1PR1MRGPRX4 | |
| SCHEMBL630601 | 0.78 | RXRA (0.50) | RXRARXRGRXRBS1PR1 | |
| SCHEMBL631128 | 0.78 | RXRA (0.50) | RXRARXRGRXRBS1PR1 | |
| SCHEMBL10029561 | 0.78 | RXRA (0.42) | RXRARXRGRXRBAKR1B1AGBL2 | |
| SCHEMBL19281422 | 0.77 | GRK6 (0.43) | RXRARXRGRXRBMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-03-29 | — | — | US | disclosed |
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-03-29 | — | — | US | disclosed |
| EP-2419412-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120741-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | RBP4, RBP1, FABP4 | RXRA 11/4885RXRG 10/4885RXRB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.